Fig. 1From: Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibitionVemurafenib bioavailability determines survival of pDCs and mDCs. Freshly isolated plasmacytoid DCs and myeloid DCs were cultured in increasing concentrations of vemurafenib and human serum and cell viability was determined after 24 h by FACS analysisBack to article page